IBM Stock: Stable Dividend or Stagnant Investment?
The AI race has heated up significantly but returns on…
Sell
32
ENLV Quote, Financials, Valuation and Earnings
Last price:
$1.19
Seasonality move
:
-21.95%
Day range:
$1.15 - $1.29
52-week range:
$0.81 - $4.59
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.98x
Volume:
470.8K
Avg. volume:
158.1K
1-year change:
-64.79%
Market cap:
$26.2M
Revenue:
--
EPS (TTM):
-$0.98
Analysts' Opinion
-
Consensus RatingEnlivex Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $9.50, Enlivex Therapeutics has an estimated upside of 698.32% from its current price of $1.19.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $6.00 representing 100% downside risk from its current price of $1.19.
Fair Value
-
According to the consensus of 1 analyst, Enlivex Therapeutics has 698.32% upside to fair value with a price target of $9.50 per share.
ENLV vs. S&P 500
-
Over the past 5 trading days, Enlivex Therapeutics has overperformed the S&P 500 by 2.33% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Enlivex Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Enlivex Therapeutics has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Enlivex Therapeutics reported revenues of --.
Earnings Growth
-
Enlivex Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Enlivex Therapeutics reported earnings per share of -$0.12.
Enterprise value:
1.7M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.12x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$25.8M | -$26.9M | -$16.1M | -$5.6M | -$3.1M | |
| EBITDA | -$25.1M | -$26M | -$15.4M | -$5.4M | -$3M | |
| Diluted EPS | -$1.57 | -$1.47 | -$0.98 | -$0.32 | -$0.12 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $31.6M | $90.3M | $59.2M | $31.8M | $27.1M | |
| Total Assets | $33.4M | $98.2M | $72.4M | $46.9M | $29.8M | |
| Current Liabilities | $4.4M | $4.7M | $4.5M | $4.3M | $2.8M | |
| Total Liabilities | $4.9M | $10.1M | $9.1M | $8.2M | $3.2M | |
| Total Equity | $28.5M | $88.1M | $63.3M | $38.8M | $26.6M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$25.7M | -$23.1M | -$14.2M | -$5.4M | -$2.6M | |
| Cash From Investing | $60.1M | -$33M | $9.8M | $3.9M | $1.4M | |
| Cash From Financing | $147K | $360K | $5.2M | -- | $250K | |
| Free Cash Flow | -$32.3M | -$25.9M | -$14.3M | -$5.5M | -$2.6M | |
ENLV
Sector
Market Cap
$26.2M
$38.8M
Price % of 52-Week High
25.93%
46.15%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-64.79%
-38.9%
Beta (5-Year)
1.106
0.773
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$1.10
200-day SMA
Sell
Level
$1.29
Bollinger Bands (100)
Sell
Level
1.04 - 1.36
Chaikin Money Flow
Sell
Level
-64.3M
20-day SMA
Buy
Level
$1.07
Relative Strength Index (RSI14)
Buy
Level
59.21
ADX Line
Buy
Level
29.1
Williams %R
Neutral
Level
-28.4657
50-day SMA
Buy
Level
$1.13
MACD (12, 26)
Buy
Level
0.00
25-day Aroon Oscillator
Buy
Level
16
On Balance Volume
Neutral
Level
95.6M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.
Stock Forecast FAQ
In the current month, ENLV has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ENLV average analyst price target in the past 3 months is $9.50.
-
Where Will Enlivex Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Enlivex Therapeutics share price will rise to $9.50 per share over the next 12 months.
-
What Do Analysts Say About Enlivex Therapeutics?
Analysts are divided on their view about Enlivex Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Enlivex Therapeutics is a Sell and believe this share price will drop from its current level to $6.00.
-
What Is Enlivex Therapeutics's Price Target?
The price target for Enlivex Therapeutics over the next 1-year time period is forecast to be $9.50 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ENLV A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Enlivex Therapeutics is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of ENLV?
You can purchase shares of Enlivex Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Enlivex Therapeutics shares.
-
What Is The Enlivex Therapeutics Share Price Today?
Enlivex Therapeutics was last trading at $1.19 per share. This represents the most recent stock quote for Enlivex Therapeutics. Yesterday, Enlivex Therapeutics closed at $1.19 per share.
-
How To Buy Enlivex Therapeutics Stock Online?
In order to purchase Enlivex Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Trimble Stock a Buy, Sell or Hold?
Trimble (NASDAQ:TRMB) is a hardware and software tech company that…
Is DraftKings Stock a Good Bet on the Future of Sports Betting?
It seems like right now is a good time to…
Stock Ideas
Buy
62
Is AAPL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 39x
Sell
47
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Sell
47
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 38x
Alerts
Buy
86
WLDN alert for Mar 10
Willdan Group [WLDN] is down 3.66% over the past day.
Buy
76
PDEX alert for Mar 10
Pro-Dex [PDEX] is up 10.33% over the past day.
Sell
7
IOT alert for Mar 10
Samsara [IOT] is down 3.68% over the past day.
